News & Presentations

Arovella funded to Phase 1 data: completes $12.5m placement

Bradley Cocks 26/3/24 Bradley Cocks 26/3/24

Arovella funded to Phase 1 data: completes $12.5m placement

Read More

Arovella enhances solid tumour pipeline by licensing novel CAR-iNKT cell armouring technology

Michelle Long 30/1/24 Michelle Long 30/1/24

Arovella enhances solid tumour pipeline by licensing novel CAR-iNKT cell armouring technology

Read More

Arovella completes key manufacturing step to progress ALA‐101 to clinic

Michelle Long 2/1/24 Michelle Long 2/1/24

Arovella completes key manufacturing step to progress ALA‐101 to clinic

Read More

Arovella receives R&D tax credit of $1.94m

Michelle Long 20/11/23 Michelle Long 20/11/23

Arovella receives R&D tax credit of $1.94m

Read More

AGM Chairman's Address and CEO & MD Presentation

Michelle Long 10/11/23 Michelle Long 10/11/23

AGM Chairman's Address and CEO & MD Presentation

Read More

Arovella licenses novel solid tumour targeting technology

Michelle Long 12/10/23 Michelle Long 12/10/23

Arovella licenses novel solid tumour targeting technology

Read More

Completion of oversubscribed Share Purchase Plan (SPP)

Michelle Long 11/7/23 Michelle Long 11/7/23

Completion of oversubscribed Share Purchase Plan (SPP)

Read More

Arovella completes $4m placement & launches $1m SPP

Michelle Long 11/7/23 Michelle Long 11/7/23

Arovella completes $4m placement & launches $1m SPP

Read More